Mitchell A. Psotka, Inova Heart and Vascular Institute
William T. Abraham, The Ohio State University
Mona Fiuzat, Duke University Medical Center and Duke Clinical Research Institute
Gerasimos Filippatos, University of Cyprus Medical School
JoAnn Lindenfeld, Vanderbilt Heart and Vascular Institute
Tariq Ahmad, Yale University School of Medicine
Ankeet S. Bhatt, Brigham and Women's Hospital
Peter E. Carson, Washington Veterans Affairs Medical Center
John G.F. Cleland, University of Glasgow
G. Michael Felker, Duke University Medical Center and Duke Clinical Research Institute
James L. Januzzi, Massachusetts General Hospital and Baim Institute for Clinical Research
Dalane W. Kitzman, Wake Forest School of Medicine
Eric S. Leifer, National Heart, Lung, and Blood Institute
Eldrin F. Lewis, Stanford University
John J.V. McMurray, University of Glasgow
Robert J. Mentz, Duke University Medical Center and Duke Clinical Research Institute
Scott D. Solomon, Brigham and Women's Hospital
Norman Stockbridge, United States Food and Drug Administration
John R. Teerlink, University of California-San Francisco
Muthiah Vaduganathan, Brigham and Women's Hospital
Orly Vardeny, Minneapolis VA Center for Care Delivery and Outcomes Research and University of Minnesota
David J. Whellan, Thomas Jefferson UniversityFollow
Janet Wittes, Statistics Collaborative, Washington, DC
Stefan D. Anker, Charité Universitätsmedizin Berlin
Christopher M. O'Connor, Inova Heart and Vascular Institute; Duke University Medical Center and Duke Clinical Research Institute

Document Type


Publication Date



This article is the author’s final published version in Journal of the American College of Cardiology, Volume 76, Issue 20, November 2020, Pages 2368-2378.

The published version is available at Copyright © Psotka et al.


The coronavirus disease-2019 (COVID-19) pandemic has profoundly changed clinical care and research, including the conduct of clinical trials, and the clinical research ecosystem will need to adapt to this transformed environment. The Heart Failure Academic Research Consortium is a partnership between the Heart Failure Collaboratory and the Academic Research Consortium, composed of academic investigators from the United States and Europe, patients, the U.S. Food and Drug Administration, the National Institutes of Health, and industry members. A series of meetings were convened to address the challenges caused by the COVID-19 pandemic, review options for maintaining or altering best practices, and establish key recommendations for the conduct and analysis of clinical trials for cardiovascular disease and heart failure. This paper summarizes the discussions and expert consensus recommendations.

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.

PubMed ID